Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 2/20 | 0.48 |
| ▸ | LYN | P07948 | 2/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | MOK | Q9UQ07 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464285 | 0.85 | MAPK14 (0.57) | MAPK14SRCABL1RAF1LYN | |
| SCHEMBL4087747 | 0.82 | MAPK14 (0.60) | MAPK14SRCABL1RAF1LYN | |
| SCHEMBL4093523 | 0.79 | MAPK14 (0.64) | MAPK14SRCABL1RAF1LYN | |
| SCHEMBL4092891 | 0.78 | MAPK14 (0.60) | MAPK14SRCABL1RAF1LYN | |
| SCHEMBL4092250 | 0.77 | MAPK14 (0.72) | MAPK14SRCABL1RAF1LYN | |
| SCHEMBL4092742 | 0.76 | MAPK14 (0.64) | MAPK14SRCABL1RAF1LYN | |
| SCHEMBL27504870 | 0.74 | MAPK14 (0.64) | MAPK14SRCABL1RAF1LYN | |
| SCHEMBL4098068 | 0.74 | MAPK14 (0.66) | MAPK14SRCABL1RAF1LYN | |
| SCHEMBL4092979 | 0.74 | MAPK14 (0.65) | MAPK14SRCABL1RAF1LYN | |
| SCHEMBL27483037 | 0.73 | MAPK14 (0.65) | MAPK14SRCABL1RAF1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BDKRB2, EDNRB, GRK5 | MAPK14 74/4885SRC 1016/4885ABL1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.